Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian
  • Portuguese
  • Polish

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Clostridioides difficile: gut microbiota markers predict the risk of infection
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
General Medicine

Breadcrumb

  1. Home
  2. Gastroenterology
  3. Clostridioides difficile: gut microbiota markers predict the risk of infection
Gastroenterology

Clostridioides difficile: gut microbiota markers predict the risk of infection

C difficile
Gastroenterology

A study conducted in six European countries has made it possible to identify the gut microbiota markers predictive of antibiotic-associated diarrhea and Clostridioides difficile infection. 

Gastroenterology
Gynecology
Pediatrics
General Medicine
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

About this article

Created 20 July 2021
Updated 19 July 2024

Dysbiosis caused by a course of antibiotics can lead to Clostridioides difficile infection. This pathogen is associated with significant morbidity and mortality, as well as high health care costs worldwide. Identifying markers of this infection could contribute to improving treatment and reducing the severity of infection.

More than 1000 patients recruited from 34 European hospitals.

In this observational, prospective, multicenter study, the gut microbiota of hospitalized patients aged over 50 years was analyzed (16S rRNA sequencing combined with an oligotyping technique for identifying C. difficile) the day before starting antibiotic therapy with the aim of identifying microbial markers predictive of antibiotic-associated diarrhea (AAD) and C. difficile infection (CDI). A longitudinal analysis was also performed to assess the impact of (sidenote: Penicillin + beta-lactamase inhibitor, other classes of beta-lactams, Fluoroquinolones )  on the gut microbiota.

Markers predictive of CDI

135 patients reported diarrhea in the 90 days following treatment, 15 of which had CDI. Researchers observed that the diversity of the microbiota on D1, prior to any antibiotic therapy, was lower in patients who had suffered CDI compared with those who had suffered AAD or patients who had not had diarrhea at all. The composition of their gut microbiota was also different: Enterococcus was more abundant, whereas there was a reduction in Blautia, Ruminococcus, Porphyromonas, Bifidobacteria, Odoribacter, Prevotella and Ezakiella spp. compared with patients who had not had CDI. Ruminococcus, Ezakiella and Odoribacter spp., five days prior to the onset of CDI in this cohort. These predictive markers were compared with those from a Canadian cohort of elderly patients who suffered CDI. In exactly the same way, the gut diversity was reduced; there was an increase in Enterococcus and a reduction in Ruminococcus, Ezakiella and Odoribacter spp. five days prior to the onset of infection.

Antibiotic-induced dysbiosis

The authors also found that antibiotics induced dysbiosis, which was classed as such six days after the start of treatment. The gut microbiota of patients taking beta-lactam antibiotics (a different class from penicillin) suffered the most disruption. All beta-lactams (regardless of whether they are combined with a beta-lactamase inhibitor or not) increase the abundance of Enterococcus. Treatment with penicillin combined with a beta-lactamase inhibitor was also associated with a reduction in bacteria belonging to the Clostridiales Incertae Sedis XI family, known for being associated with a reduced risk of CDI. The other classes of beta-lactams induced a reduction in bacteria belonging to Lachnospiraceae, including butyrate-producing species, known for their beneficial effects on health. Collectively, all the classes of antibiotics studied considerably altered the composition of the gut microbiota and are well documented, as they involve a high risk of developing CDI.

 

Sources

Berkell M., Mysara M., Xavier B.B. et al. Microbiota-based markers predictive of development of Clostridioides difficile infection. Nat Commun. 2021 Apr 14;12(1):2241

Old sources

 

 

Tags
Diarrhea CDI Microbiome Flora
    Created 20 July 2021
    Updated 19 July 2024

    About this article

    To know more about this topic.

    Main topic

    C difficile

    Medical practice

    Gastroenterology

    Content type

    News
    Gastroenterology

    Association between fungal dysbiosis and environment

    The fungal portion of the gut microbiota (or mycobiota) has been much less studied than the bacterial...

    Find out more

    Your IBS Diagnosis Check List

    How many patients suffering from gut disorder do you see per week? How many are diagnosed with Irrita...

    Find out more

    Probiotics: what exactly are we talking about?

    From the Latin pro and Greek bios meaning “for life”, the term “probiotic” was suggested over 60 year...

    Find out more

    How do you choose a probiotic for your patient?

    Faced with a plethora of products on the market, it's not always easy for health professionals to sug...

    Find out more

    The Janus face of Antibiotics: Life Savers and Microbiota Disruptors

    A page turns: with the advent of antibiotics in the...

    Find out more

    Fecal transplantation - ready for prime time?

    Congress review By Pr. Danny De Looze Department of Gastroenterology University Hospital Gent, Belgi...

    Find out more

    Focus on antibiotic associated diarrhea (AAD)

    Find out more

    Dampening gastrointestinal inflammation through nutrition

    by Dr Genelle Healey

    Find out more

    Continue reading

    News
    Actu PRO : Malnutrition : agir sur le microbiote pour améliorer la croissance, un prototype à l’essai
    08.07.2021

    Malnutrition: acting on the microbiota in order to improve growth, a trial prototype

    Read the article
    07.05.2025

    The microbial-metabolic nexus in colon cancer

    Read the article
    07.02.2025

    Your functional dyspepsia diagnosis check list

    Read the article
    17.04.2025

    Sensitivity to the additive E466: the role of the microbiota

    Read the article
    Photo HCPs: Clinical context over quick fix: the fresh consensus on microbiome testing
    11.04.2025

    Clinical context over quick fix: the fresh consensus on microbiome testing

    Read the article
    22.11.2023

    Is vaginal microbiota transfer the new miracle for C-section babies?

    Read the article
    Actu PRO : Alcoolisme : expliquer les troubles sociaux grâce au microbiote
    27.01.2021

    Alcoholism: explaining social disorders thanks to the microbiota

    Read the article
    20.03.2025

    Entacapone and the gut: a hidden impact on parkinson’s care

    Read the article
    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine
    • English
    • Français
    • Español
    • Russian
    • Portuguese
    • Polish

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    14.05.2025

    Towards worldwide redefinition of healthy vaginal microbiota

    Read the article
    07.05.2025

    The microbial-metabolic nexus in colon cancer

    Read the article
    02.05.2025

    A new lens on chlamydia: beyond behavior, into the microbiome

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    © 2025 Biocodex. All rights reserved.

    • Legal notice
    • GTU
    • Data protection policy
    • Sitemap
    • Cookies settings
    • Digital accessibility : partially compliant
    Biocodex logo